B7 Transfected Melanoma Cell Vaccine
An allogenic whole tumor cell vaccine with potential antineoplastic activity. B7 transfected melanoma cell vaccine consists of melanoma cells that have been induced to express the human leukocyte antigen (HLA) B7. Vaccination with these altered cells may elicit an anti-tumor immune response via CD8+ cytotoxic T lymphocytes (CTL). (NCI04) [ ]
Term info
B7 Transfected Melanoma Cell Vaccine
- B7 Transfected Allogenic Melanoma Cell Vaccine
- B7 Transfected Melanoma Cell Vaccine
NCIT_C128784
B7_Transfected_Melanoma_Cell_Vaccine
666059
B7 Transfected Melanoma Cell Vaccine
Pharmacologic Substance, Immunologic Factor
C1516106
C2745
Term relations
- Melanoma Vaccine
- Chemical_Or_Drug_Affects_Cell_Type_Or_Tissue some Cytotoxic T-Lymphocyte
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Gene Regulation Process
- Chemical_Or_Drug_Has_Physiologic_Effect some T-Cell Receptor Activation
- Chemical_Or_Drug_Has_Physiologic_Effect some Immunopotentiation